Saad Z. Usmani, MD, MBA, FACP | Authors

Transplant-Ineligible Multiple Myeloma: Triplet vs Quadruplet Therapy

February 08, 2022

Considerations for selecting between a conventional front-line triplet regimen to manage a patient with high-risk multiple myeloma who is ineligible for transplant vs a new quadruplet regimen, as demonstrated in recent clinical trial data.